Ocular Therapeutix (NASDAQ:OCUL) Director Buys $461,354.14 in Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Director Richard Md Lindstrom purchased 60,229 shares of the firm’s stock in a transaction on Friday, February 20th. The stock was bought at an average cost of $7.66 per share, with a total value of $461,354.14. Following the completion of the purchase, the director owned 246,933 shares of the company’s stock, valued at approximately $1,891,506.78. This represents a 32.26% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Ocular Therapeutix Stock Up 6.4%

Shares of OCUL stock traded up $0.54 on Tuesday, reaching $8.95. 6,321,431 shares of the company were exchanged, compared to its average volume of 7,037,731. The company has a debt-to-equity ratio of 0.11, a current ratio of 15.39 and a quick ratio of 15.32. The company has a 50-day moving average of $10.64 and a 200-day moving average of $11.64. The company has a market cap of $1.95 billion, a price-to-earnings ratio of -6.22 and a beta of 0.90. Ocular Therapeutix, Inc. has a one year low of $5.78 and a one year high of $16.44.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. Ocular Therapeutix had a negative return on equity of 70.68% and a negative net margin of 511.90%.The business had revenue of $13.25 million for the quarter, compared to the consensus estimate of $16.13 million. During the same period in the prior year, the business earned ($0.29) EPS. The firm’s revenue for the quarter was down 22.4% on a year-over-year basis. Analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Steward Partners Investment Advisory LLC raised its stake in Ocular Therapeutix by 124.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,242 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Ocular Therapeutix by 1.8% in the second quarter. The Manufacturers Life Insurance Company now owns 72,618 shares of the biopharmaceutical company’s stock worth $674,000 after purchasing an additional 1,314 shares in the last quarter. Nisa Investment Advisors LLC raised its position in shares of Ocular Therapeutix by 62.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 1,392 shares during the period. Trust Co. of Vermont lifted its stake in shares of Ocular Therapeutix by 24.3% during the 4th quarter. Trust Co. of Vermont now owns 8,950 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,750 shares in the last quarter. Finally, Profund Advisors LLC boosted its holdings in Ocular Therapeutix by 9.9% in the 3rd quarter. Profund Advisors LLC now owns 25,178 shares of the biopharmaceutical company’s stock worth $294,000 after buying an additional 2,272 shares during the period. Institutional investors own 59.21% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Thursday, January 22nd. Needham & Company LLC lowered their target price on shares of Ocular Therapeutix from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Friday. Chardan Capital reaffirmed a “buy” rating and issued a $21.00 price target on shares of Ocular Therapeutix in a research report on Wednesday, February 18th. Royal Bank Of Canada reissued an “outperform” rating and set a $30.00 price objective on shares of Ocular Therapeutix in a report on Thursday, February 5th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Ocular Therapeutix in a research report on Tuesday, February 17th. Twelve research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Ocular Therapeutix currently has an average rating of “Moderate Buy” and a consensus target price of $23.78.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.